Growth hormone and tesamorelin in the management of HIV-associated lipodystrophy

References

• BrodtHRKampsBSGutePKnuppBStaszewskiSHelmEBChanging incidence of AIDS-defining illnesses in the era of antiretroviral combination therapyAIDS19971114173117389386808
   PubMed Web of Science ®Google Scholar
• MichaelsSHClarkRKissingerPDeclining morbidity and mortality among patients with advanced human immunodeficiency virus infectionN Engl J Med199833964054069696654
   PubMed Web of Science ®Google Scholar
• PalellaFJJrDelaneyKMMoormanACDeclining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study InvestigatorsN Engl J Med1998338138538609516219
   PubMed Web of Science ®Google Scholar
• SepkowitzKAEffect of HAART on natural history of AIDS-related opportunistic disordersLancet199835190982282309457088
   PubMed Web of Science ®Google Scholar
• DetelsRMunozAMcFarlaneGKingsleyLAMargolickJBGiorgiJEffectiveness of potent antiretroviral therapy on time to AIDS and death in men with known HIV infection duration. Multicenter AIDS Cohort Study InvestigatorsJAMA199828017149715039809730
   PubMed Web of Science ®Google Scholar
• KaplanJEHansonDDworkinMSEpidemiology of human immunodeficiency virus-associated opportunistic infections in the United States in the era of highly active antiretroviral therapyClin Infect Dis200030Suppl 1S5S1410770911
   PubMed Web of Science ®Google Scholar
• MurphyELCollierACKalishLAHighly active antiretroviral therapy decreases mortality and morbidity in patients with advanced HIV diseaseAnn Intern Med20011351172611434728
   PubMed Web of Science ®Google Scholar
• ValdezHChowdhryTKAsaadRChanging spectrum of mortality due to human immunodeficiency virus: analysis of 260 deaths during 1995–1999Clin Infect Dis200132101487149311317251
   PubMed Web of Science ®Google Scholar
• CarrASamarasKBurtonSA syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitorsAIDS1998127F51F589619798
   PubMed Web of Science ®Google Scholar
• LoJCMulliganKTaiVWAlgrenHSchambelanM“Buffalo hump” in men with HIV-1 infectionLancet199835191068678709525364
   PubMed Web of Science ®Google Scholar
• VirabenRAquilinaCIndinavir-associated lipodystrophyAIDS1998126F37F399583592
   PubMed Web of Science ®Google Scholar
• GargAAcquired and inherited lipodystrophiesN Engl J Med2004350121220123415028826
   PubMed Web of Science ®Google Scholar
• BarbaroGVisceral fatas target of highly active antiretroviral therapy- associated metabolic syndromeCurr Pharm Des200713212208221317627554
   PubMed Web of Science ®Google Scholar
• QiaoQGaoWZhangLNyamdorjRTuomilehtoJMetabolic syndrome and cardiovascular diseaseAnn Clin Biochem200744Pt 323226317456293
   PubMed Web of Science ®Google Scholar
• ChenDMisraAGargAClinical review 153: lipodystrophy in human immunodeficiency virus-infected patientsJ Clin Endocrinol Metab200287114845485612414837
   PubMed Web of Science ®Google Scholar
• TienPCColeSRWilliamsCMIncidence of lipoatrophy and lipohypertrophy in the women’s interagency HIV studyJ Acquir Immune Defic Syndr200334546146614657755
   PubMed Web of Science ®Google Scholar
• JacobsonDLKnoxTSpiegelmanDSkinnerSGorbachSWankeCPrevalence of, evolution of, and risk factors for fat atrophy and fat deposition in a cohort of HIV-infected men and womenClin Infect Dis200540121837184515909274
   PubMed Web of Science ®Google Scholar
• BlanchJRousaudAMartinezEFactors associated with severe impact of lipodystrophy on the quality of life of patients infected with HIV-1Clin Infect Dis200438101464147015156486
   PubMed Web of Science ®Google Scholar
• MorriconeLDonatiCHassanTCioffiPCaviezelFRelationship of visceral fat distribution to angiographically assessed coronary artery disease: results in subjects with or without diabetes or impaired glucose toleranceNutr Metab Cardiovasc Dis200212527528312616807
   PubMed Web of Science ®Google Scholar
• CofrancescoJJrFreedlandEMcComseyGTreatment options for HIV-associated central fat accumulationAIDS Patient Care STDS200923151819055407
   PubMed Web of Science ®Google Scholar
• El-SadrWMLundgrenJDNeatonJDCD4+ count-guided interruption of antiretroviral treatmentN Engl J Med2006355222283229617135583
   PubMed Web of Science ®Google Scholar
• HadiganCCorcoranCBasgozNDavisBSaxPGrinspoonSMetformin in the treatment of HIV lipodystrophy syndrome: a randomized controlled trialJAMA2000284447247710904511
   PubMed Web of Science ®Google Scholar
• MulliganKYangYWiningerDAEffects of metformin and rosiglitazone in HIV-infected patients with hyperinsulinemia and elevated waist/hip ratioAIDS2007211475717148967
   PubMed Web of Science ®Google Scholar
• HultmanCSMcPhailLEDonaldsonJHWohlDASurgical management of HIV-associated lipodystrophy: role of ultrasonic-assisted liposuction and suction-assisted lipectomy in the treatment of lipohypertrophyAnn Plast Surg200758325526317471128
   PubMed Web of Science ®Google Scholar
• MestDRHumbleGSafety and efficacy of poly-L-lactic acid injections in persons with HIV-associated lipoatrophy: the US experienceDermatol Surg200632111336134517083585
   PubMed Web of Science ®Google Scholar
• SilversSLEviatarJAEchavezMIPappasALProspective, open- label, 18-month trial of calcium hydroxylapatite (Radiesse) for facial soft- tissue augmentation in patients with human immunodeficiency virus-associated lipoatrophy: one-year durabilityPlast Reconstr Surg2006118Suppl 334S45S16936543
   PubMed Web of Science ®Google Scholar
• RietschelPHadiganCCorcoranCAssessment of growth hormone dynamics in human immunodeficiency virus-related lipodystrophyJ Clin Endocrinol Metab200186250451011158000
   PubMed Web of Science ®Google Scholar
• BehrensGSchmidtRELypodystrophy syndromeHoffmannCRockstrohJKKampsBSHIV Medicine 200614th edParis FranceFlying Publisher2006301316
   Google Scholar
• LichtensteinKARedefining lipodystrophy syndrome: risks and impact on clinical decision makingJ Acquir Immune Defic Syndr200539439540016010159
   PubMed Web of Science ®Google Scholar
• CarrAHIV lipodystrophy: risk factors, pathogenesis, diagnosis and managementAIDS200317 Suppl 1S14114812870540
   PubMed Web of Science ®Google Scholar
• LawMPulsRChengAKCooperDACarrAEvaluation of the HIV lipodystrophy case definition in a placebo-controlled, 144-week study in antiretroviral-naive adultsAntivir Ther200611217918616640099
   PubMed Web of Science ®Google Scholar
• BacchettiPGripshoverBGrunfeldCFat distribution in men with HIV infectionJ Acquir Immune Defic Syndr200540212113116186728
   PubMed Web of Science ®Google Scholar
• DingesWLChenDSnellPGWeatherallPTPetersonDMGargARegional body fat distribution in HIV-infected patients with lipodystrophyJ Investig Med20055311525
   PubMed Web of Science ®Google Scholar
• BacchettiPCofrancescoJHeymsfieldSFat distribution in women with HIV infectionJ Acquir Immune Defic Syndr200642556257116837863
   PubMed Web of Science ®Google Scholar
• MulliganKParkerRAKomarowLMixed patterns of changes in central and peripheral fat following initiation of antiretroviral therapy in a randomized trialJ Acquir Immune Defic Syndr200641559059716652032
   PubMed Web of Science ®Google Scholar
• GrinspoonSCarrACardiovascular risk and body-fat abnormalities in HIV-infected adultsN Engl J Med20053521486215635112
   PubMed Web of Science ®Google Scholar
• WohlDAMcComseyGTebasPCurrent concepts in the diagnosis and management of metabolic complications of HIV infection and its therapyClin Infect Dis200643564565316886161
   PubMed Web of Science ®Google Scholar
• StanleyTLJoyTHadiganCMEffects of switching from lopinavir/ritonavir to atazanavir/ritonavir on muscle glucose uptake and visceral fat in HIV-infected patientsAIDS200923111349135719474651
   PubMed Web of Science ®Google Scholar
• MoyleGJGirardJMAndradeJContinuation of BID boosted PI vs switch to once-daily ATV/RTV for the management of lipodystrophy: 48 week primary analysis of the 96 week multicenter, open-label, randomized, prospective REAL studyXVII International AIDS ConferenceMexico City, Mexico2008
   Google Scholar
• MoyleGJBaldwinCLangroudiBMandaliaSGazzardBGA 48-week, randomized, open-label comparison of three abacavir-based substitution approaches in the management of dyslipidemia and peripheral lipoatrophyJ Acquir Immune Defic Syndr2003331222812792351
   PubMed Web of Science ®Google Scholar
• FisacCFumeroECrespoMRosonBFerrerEVirgiliNMetabolic benefits 24 months after replacing a protease inhibitor with abacavir, efavirenz or nevirapineAIDS200519991792515905672
   PubMed Web of Science ®Google Scholar
• CarrAWorkmanCSmithDEAbacavir substitution for nucleoside analogs in patients with HIV lipoatrophy: a randomized trialJAMA2002288220721512095385
   PubMed Web of Science ®Google Scholar
• MoyleGJSabinCACartledgeJA randomized comparative trial of tenofovir DF or abacavir as replacement for a thymidine analogue in persons with lipoatrophyAIDS200620162043205017053350
   PubMed Web of Science ®Google Scholar
• TebasPZhangJHafnerRPeripheral and visceral fat changes following a treatment switch to a non-thymidine analogue or a nucleoside-sparing regimen in HIV-infected subjects with peripheral lipoatrophy: results of ACTG A5110J Antimicrob Chemother2009635998100519299471
   PubMed Web of Science ®Google Scholar
• Radiesse®Prescribing informationBioForm Medical, Inc.2006
   Google Scholar
• Sculptra™Prescribing informationDermik Laboratories2004
   Google Scholar
• CareyDBakerDEaseyNPoly-L-lactic acid injections for facial lipoatrophy: a randomized, multicenter trial14th Conference on Retroviruses and Opportunistic InfectionsLos Angeles, CA2007
   Google Scholar
• Expert Panel on Detection E, Treatment of High Blood Cholesterol in AdultsExecutive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)JAMA2001285192486249711368702
   PubMed Web of Science ®Google Scholar
• FitchKVAndersonEJHubbardJLEffects of a lifestyle modification program in HIV-infected patients with the metabolic syndromeAIDS200620141843185016954725
   PubMed Web of Science ®Google Scholar
• ThoniGJFedouCBrunJFReduction of fat accumulation and lipid disorders by individualized light aerobic training in human immunodeficiency virus infected patients with lipodystrophy and/or dyslipidemiaDiabetes Metab200228539740412461477
   PubMed Web of Science ®Google Scholar
• TungsiripatMBejjaniDERizkNRosiglitazone improves lipoatrophy in patients receiving thymidine-sparing regimensAIDS20102491291129820453626
   PubMed Web of Science ®Google Scholar
• BhasinSParkerRASattlerFEffects of testosterone supplementation on whole body and regional fat mass and distribution in human immunodeficiency virus-infected men with abdominal obesityJ Clin Endocrinol Metab20079231049105717164307
   PubMed Web of Science ®Google Scholar
• LichtensteinKBalasubramanyamASekharRFreedlandEHIV- associated adipose redistribution syndrome (HARS): etiology and pathophysiological mechanismsAIDS Res Ther200741417597538
   PubMedGoogle Scholar
• GiraltMDomingoPGuallarJPHIV-1 infection alters gene expression in adipose tissue, which contributes to HIV-1/HAART-associated lipodystrophyAntivir Ther200611672974017310817
   PubMed Web of Science ®Google Scholar
• GougeonMLPenicaudLFromentyBLeclercqPViardJPCapeauJAdipocytes targets and actors in the pathogenesis of HIV-associated lipodystrophy and metabolic alterationsAntivir Ther20049216117715134178
   PubMed Web of Science ®Google Scholar
• KershawEEFlierJSAdipose tissue as an endocrine organJ Clin Endocrinol Metab20048962548255615181022
   PubMed Web of Science ®Google Scholar
• VigourouxCMaachiMNguyenTHSerum adipocytokines are related to lipodystrophy and metabolic disorders in HIV-infected men under antiretroviral therapyAIDS200317101503151112824788
   PubMed Web of Science ®Google Scholar
• JohnsonJAAlbuJBEngelsonESIncreased systemic and adipose tissue cytokines in patients with HIV-associated lipodystrophyAm J Physiol Endocrinol Metab20042862E261E27114532165
   PubMed Web of Science ®Google Scholar
• BastardJPCaronMVidalHAssociation between altered expression of adipogenic factor SREBP1 in lipoatrophic adipose tissue from HIV-1-infected patients and abnormal adipocyte differentiation and insulin resistanceLancet200235993111026103111937183
   PubMed Web of Science ®Google Scholar
• TsiodrasSMantzorosCLeptin and Adiponectin in the HIV Associated Metabolic Syndrome: Physiologic and Therapeutic ImplicationsAm J Infect Dis20062314115217183414
   PubMedGoogle Scholar
• NagyGSTsiodrasSMartinLDHuman immunodeficiency virus type 1-related lipoatrophy and lipohypertrophy are associated with serum concentrations of leptinClin Infect Dis200336679580212627366
   PubMed Web of Science ®Google Scholar
• SutinenJKorsheninnikovaEFunahashiTMatsuzawaYNymanTYki-JarvinenHCirculating concentration of adiponectin and its expression in subcutaneous adipose tissue in patients with highly active antiretroviral therapy-associated lipodystrophyJ Clin Endocrinol Metab20038841907191012679491
   PubMed Web of Science ®Google Scholar
• NolanDMallalSComplications associated with NRTI therapy: update on clinical features and possible pathogenic mechanismsAntivir Ther20049684986315651744
   PubMed Web of Science ®Google Scholar
• McComseyGAWalkerUARole of mitochondria in HIV lipoatrophy: insight into pathogenesis and potential therapiesMitochondrion200442–311111816120376
   PubMed Web of Science ®Google Scholar
• SekharRVJahoorFWhiteACMetabolic basis of HIV-lipodystrophy syndromeAm J Physiol Endocrinol Metab20022832E332E33712110539
   PubMed Web of Science ®Google Scholar
• BalasubramanyamASekharRVJahoorFJonesPHPownallHJPathophysiology of dyslipidemia and increased cardiovascular risk in HIV lipodystrophy: a model of ‘systemic steatosis’Curr Opin Lipidol2004151596715166810
   PubMed Web of Science ®Google Scholar
• PacentiMBarzonLFavarettoFMicroarray analysis during adipogenesis identifies new genes altered by antiretroviral drugsAIDS200620131691170516931933
   PubMed Web of Science ®Google Scholar
• MallonPWSedwellRRogersGEffect of rosiglitazone on peroxisome proliferator-activated receptor gamma gene expression in human adipose tissue is limited by antiretroviral drug-induced mitochondrial dysfunctionJ Infect Dis2008198121794180318954260
   PubMed Web of Science ®Google Scholar
• El HadriKGlorianMMonsempesCDieudonneMNPecqueryRGiudicelliYIn vitro suppression of the lipogenic pathway by the nonnucleoside reverse transcriptase inhibitor efavirenz in 3T3 and human preadipocytes or adipocytesJ Biol Chem200427915151301514114722061
   PubMed Web of Science ®Google Scholar
• O’ConnorKOStevensTEBlackmanMRGrowth hormone and agingJuulAJorgensenJOLGrowth Hormone in AdultsCambridge, UKCambridge University Press1996323366
   Google Scholar
• KoutkiaPCanavanBBreuJGrinspoonSGrowth hormone (GH) responses to GH-releasing hormone-arginine testing in human immunodeficiency virus lipodystrophyJ Clin Endocrinol Metab2005901323815483073
   PubMed Web of Science ®Google Scholar
• BengtssonBAEdenSLonnLTreatment of adults with growth hormone (GH) deficiency with recombinant human GHJ Clin Endocrinol Metab19937623093178432773
   PubMed Web of Science ®Google Scholar
• LoJCMulliganKNoorMAThe effects of recombinant human growth hormone on body composition and glucose metabolism in HIV-infected patients with fat accumulationJ Clin Endocrinol Metab20018683480348711502767
   PubMed Web of Science ®Google Scholar
• EngelsonESGlesbyMJMendezDEffect of recombinant human growth hormone in the treatment of visceral fat accumulation in HIV infectionJ Acquir Immune Defic Syndr2002304379379112138344
   PubMed Web of Science ®Google Scholar
• KotlerDPMuurahainenNGrunfeldCEffects of growth hormone on abnormal visceral adipose tissue accumulation and dyslipidemia in HIV-infected patientsJ Acquir Immune Defic Syndr200435323925215076238
   PubMed Web of Science ®Google Scholar
• GrunfeldCThompsonMBrownSJRecombinant human growth hormone to treat HIV-associated adipose redistribution syndrome: 12 week induction and 24-week maintenance therapyJ Acquir Immune Defic Syndr200745328629717592343
   PubMed Web of Science ®Google Scholar
• LoJYouSMCanavanBLow-dose physiological growth hormone in patients with HIV and abdominal fat accumulation: a randomized controlled trialJAMA2008300550951918677023
   PubMed Web of Science ®Google Scholar
• KoutkiaPCanavanBBreuJTorrianiMKisskoJGrinspoonSGrowth hormone-releasing hormone in HIV-infected men with lipodystrophy: a randomized controlled trialJAMA2004292221021815249570
   PubMed Web of Science ®Google Scholar
• TomlinsonBDrug evaluation: tesamorelin, a synthetic human growth hormone releasing factorCurr Opin Investig Drugs2006710936945
   Google Scholar
• WangYTomlinsonBTesamorelin, a human growth hormone releasing factor analogueExpert Opin Investig Drugs2009183303310
   PubMed Web of Science ®Google Scholar
• FerdinandiESBrazeauPHighKProcterBFennellSDubreuilPNon-clinical pharmacology and safety evaluation of TH9507, a human growth hormone-releasing factor analogueBasic Clin Pharmacol Toxicol20071001495817214611
   PubMed Web of Science ®Google Scholar
• FalutzJAllasSKotlerDA placebo-controlled, dose-ranging study of a growth hormone releasing factor in HIV-infected patients with abdominal fat accumulationAIDS200519121279128716052083
   PubMed Web of Science ®Google Scholar
• FalutzJAllasSBlotKEffects of TH9507, a growth hormone releasing factor analog, on HIV-associated abdominal fat accumulation: A multicenter, double-blind placebo-controlled trial with 412 randomized patients14th Conference on Retroviruses and Opportunistic Infections (CROI)Los Angeles, CA2007
   Google Scholar
• FalutzJAllasSBlotKPotvinDKotlerDSomeroMMetabolic effects of a growth hormone-releasing factor in patients with HIVN Engl J Med2007357232359237018057338
   PubMed Web of Science ®Google Scholar
• FalutzJPotvinDMamputuJCAssaadHZoltowskaMMichaudSEEffects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extensionJ Acquir Immune Defic Syndr201053331132220101189
   PubMed Web of Science ®Google Scholar
• FalutzJMamputuJCPotvinDEffects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension dataJ Clin Endocrinol Metab20109594291430420554713
   PubMed Web of Science ®Google Scholar
• NakamuraTKobayashiHYanagiKImportance of intra-abdominal visceral fat accumulation to coronary atherosclerosis in heterozygous familial hypercholesterolaemiaInt J Obes Relat Metab Disord19972175805869226489
   PubMed Web of Science ®Google Scholar